Suchergebnisse - "Cortesi, Laura"

PubPharm (11)

1

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer : The randomized Tempo Breast study

enthalten in: Breast (Edinburgh, Scotland) | 2024

von Freyer, G. | Martinez-Jañez, N. | Kukielka-Budny, B. | +17

2

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Llombart-Cussac, A. | Pérez-García, J. | Bellet, M. | +52

ErratumIn: JAMA Oncol. 2021 Nov 1;7(11):1729. - PMID 34792545

3

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC) : an Italian real-world experience (HERMIONE 9)

enthalten in: Breast cancer research and treatment | 2021

von Torrisi, R. | Palumbo, R. | De Sanctis, R. | +12

4

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer : to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials

enthalten in: BMC cancer | 2020

von Omarini, C. | Piacentini, F. | Sperduti, I. | +7

5

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

enthalten in: Breast cancer research and treatment | 2019

von Nanni, O. | Amadori, D. | De Censi, A. | +23

6

Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status

enthalten in: Journal of cancer research and clinical oncology | 2019

von Omarini, C. | Bettelli, S. | Caprera, C. | +12

7

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

enthalten in: Cancer biology & therapy | 2018

von Omarini, C. | Bettelli, S. | Caprera, C. | +11

8

Twenty-years experience with de novo metastatic breast cancer

enthalten in: International journal of cancer | 2015

von Cortesi, L. | Toss, A. | Cirilli, C. | +4

9

Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence

enthalten in: Tumori | 2015

von Bogina, G. | Lunardi, G. | Coati, F. | +21

10

Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

enthalten in: International journal of cancer | 2013

von Cortesi, L. | Marcheselli, L. | Guarneri, V. | +7